[{"indications": "Indications\u00a0see under Dose; HRT (section 6.4.1.1); contraception (section 7.3.1 and section 7.3.2); malignant disease (section\r\n8.3.2)", "name": "NORETHISTERONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.2 Progestogens"], "cautions": "Cautions\u00a0\n(From 6.4.1.2 Progestogens: British National Formulary)\nCautions\u00a0Progestogens should be used with caution in conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, and in those susceptible to thromboembolism (particular caution with high dose). Care is also required in those with a history of depression. Progestogens can decrease glucose tolerance and patients with diabetes should be monitored closely. For interactions see Appendix 1 (progestogens).", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4350.htm", "doses": ["Endometriosis, by mouth, 10\u201315\u00a0mg daily\r\nfor 4\u20136 months or longer, starting on day 5 of cycle (if spotting\r\noccurs increase dose to 20\u201325\u00a0mg daily, reduced once bleeding has\r\nstopped)", "Dysfunctional uterine bleeding, menorrhagia (but see notes above), by mouth, 5\u00a0mg 3 times daily for 10 days to arrest bleeding;\r\nto prevent bleeding 5\u00a0mg twice daily from day 19 to 26", "Dysmenorrhoea (but see notes above), by mouth, 5\u00a0mg 3 times daily from day 5 to 24 for 3\u20134 cycles", "Premenstrual syndrome (but not recommended, see notes above), by mouth, 5\u00a0mg 2\u20133 times daily from day 19 to 26 for several\r\ncycles", "Postponement of menstruation, by mouth, 5\u00a0mg\r\n3 times daily starting 3 days before expected onset (menstruation\r\noccurs 2\u20133 days after stopping)"], "pregnancy": "Pregnancy\u00a0section 8.3.2"}, {"indications": "Indications\u00a0\n(From 8.3.2 Progestogens: British National Formulary)\n8.3.2 Progestogens; other indications (%s\n(From 6.4.1.2 Progestogens: British National Formulary)\n6.4.1.2 Progestogens)", "name": "NORETHISTERONE - SEX HORMONES AND HORMONE ANTAGONISTS IN MALIGNANT DISEASE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.2 Progestogens", "NORETHISTERONE"], "cautions": "Cautions\u00a0see section\r\n6.4.1.2 and notes above; interactions: Appendix 1 (progestogens)", "side-effects": "Side-effects\u00a0see section\r\n6.4.1.2 and notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/100123.htm", "doses": ["Breast cancer, 40\u00a0mg daily, increased to 60\u00a0mg daily if\r\nrequired"], "pregnancy": "Pregnancy\u00a0masculinisation of female fetuses and other defects\r\nreported; see also oral Progestogen-only Contraceptives (section 7.3.2.1)"}, {"indications": "Indications\u00a0see under Dose; HRT (section 6.4.1.1); contraception (section 7.3.1 and section 7.3.2); malignant disease (section\r\n8.3.2)", "name": "NORETHISTERONE - FEMALE SEX HORMONES", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.1 Female sex hormones", "6.4.1.2 Progestogens"], "cautions": "Cautions\u00a0\n(From 6.4.1.2 Progestogens: British National Formulary)\nCautions\u00a0Progestogens should be used with caution in conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, and in those susceptible to thromboembolism (particular caution with high dose). Care is also required in those with a history of depression. Progestogens can decrease glucose tolerance and patients with diabetes should be monitored closely. For interactions see Appendix 1 (progestogens).", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4350.htm", "doses": ["Endometriosis, by mouth, 10\u201315\u00a0mg daily\r\nfor 4\u20136 months or longer, starting on day 5 of cycle (if spotting\r\noccurs increase dose to 20\u201325\u00a0mg daily, reduced once bleeding has\r\nstopped)", "Dysfunctional uterine bleeding, menorrhagia (but see notes above), by mouth, 5\u00a0mg 3 times daily for 10 days to arrest bleeding;\r\nto prevent bleeding 5\u00a0mg twice daily from day 19 to 26", "Dysmenorrhoea (but see notes above), by mouth, 5\u00a0mg 3 times daily from day 5 to 24 for 3\u20134 cycles", "Premenstrual syndrome (but not recommended, see notes above), by mouth, 5\u00a0mg 2\u20133 times daily from day 19 to 26 for several\r\ncycles", "Postponement of menstruation, by mouth, 5\u00a0mg\r\n3 times daily starting 3 days before expected onset (menstruation\r\noccurs 2\u20133 days after stopping)"], "pregnancy": "Pregnancy\u00a0section 8.3.2"}]